Radiation Oncology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China.
Department of Respiratory Disease, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Cancer Invest. 2020 Jan;38(1):13-22. doi: 10.1080/07357907.2019.1697281. Epub 2019 Dec 6.
Cancer stem cells are self-renewal cells in tumors and can produce heterogeneous tumor cells, which play an important role in the development of lung squamous cell carcinoma (LSCC). In our research, we aimed to explore the expression of genes related to LSCC stem cells. We downloaded the RNAseq data, the pathological and prognostic profiles of LSCC cases from the public database TCGA. The mRNA expression-based stiffness index (mRNAsi) of LSCC was calculated and the prognostic value of mRNAsi was discussed. Then, we constructed a weighted gene co-expression network analysis (WGCNA) to screen key genes related to mRNAsi of LSCC. MRNAsi is an independent prognostic factor in LSCC. We screened 5 key genes (BUB1, BIRC5, CCNB2, KIF15 and SPAG5) related to mRNAsi of LSCC based on WGCNA. The key genes were highly expressed in the tumor samples compared to the normal samples. In addition, there is a strong interaction between proteins of these key genes and a strong co-expression relationship at the transcriptional level. To conclude, mRNAsi play an important role in LSCC. Five key genes (BUB1, BIRC5, CCNB2, KIF15 and SPAG5) related to mRNAsi were screened, which may act as therapeutic targets for inhibiting the stem cell characteristics of LSCC.
肿瘤干细胞是肿瘤中的自我更新细胞，能够产生异质性肿瘤细胞，在肺鳞状细胞癌（LSCC）的发展中起重要作用。在我们的研究中，我们旨在探索与 LSCC 干细胞相关的基因表达。我们从公共数据库 TCGA 下载了 LSCC 病例的 RNAseq 数据、病理和预后资料。计算了基于 mRNA 表达的 LSCC 刚性指数（mRNAsi），并讨论了 mRNAsi 的预后价值。然后，我们构建了加权基因共表达网络分析（WGCNA）来筛选与 LSCC 的 mRNAsi 相关的关键基因。mRNAsi 是 LSCC 的一个独立预后因素。我们基于 WGCNA 筛选了与 LSCC 的 mRNAsi 相关的 5 个关键基因（BUB1、BIRC5、CCNB2、KIF15 和 SPAG5）。这些关键基因在肿瘤样本中的表达水平高于正常样本。此外，这些关键基因的蛋白质之间存在强烈的相互作用，在转录水平上具有强烈的共表达关系。总之，mRNAsi 在 LSCC 中起重要作用。筛选出与 mRNAsi 相关的 5 个关键基因（BUB1、BIRC5、CCNB2、KIF15 和 SPAG5），它们可能作为抑制 LSCC 干细胞特性的治疗靶点。
